Engineering T cells for cancer therapy: progress and challenges

Carl June1

1Perelman School of Medicine at thr University of Pennsylvania, Philadelphia, USA


It is now well established that the immune system can control and eliminate
cancer cells. Adoptive T cell transfer has the potential to overcome the significant
limitations associated with vaccine-based strategies in patients
who are often immune compromised. Application of the emerging discipline
of synthetic biology to cancer, which combines elements of genetic engineering
and molecular biology to create new biological structures with enhanced
functionalities, is the subject of this presentation. Various chimeric antigen
receptor designs, manufacturing processes and study populations, among
other variables, have been tested and reported in recent clinical trials.
Many questions remain in the field of engineered T cells, but the encouraging
response rates pave a wide road for future investigation into many, if not all, forms of cancer.